Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Background Hepatitis B virus (HBV ... to identify all orders for HBsAg within a 17 month time period. Detailed chart review was performed to identify all patients who were administered HBV ...

More than 30,000 people have already benefited from new drugs to treat hepatitis C and the death rate from related liver diseases has already fallen by more than 16% between 2015 and 2017.

Less than three years after Sovaldi’s launch, hepatitis C (hep C) treatment has been transformed, thanks to the drug and rapidly-evolving competition in the field. But only a small percentage of ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...